Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.
about
Classical and recent advances in the treatment of inflammatory bowel diseasesEfficacy of early immunomodulator therapy on the outcomes of Crohn's disease.Use of thiopurines in inflammatory bowel disease: Safety issues.Making therapeutic decisions in inflammatory bowel disease: the role of patients.Routine use of thiopurines in maintaining remission in pediatric Crohn's disease.Current status of thiopurine analogues in the treatment in Crohn's disease.Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy.Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's diseaseProgress in the treatment and outcome of pediatric inflammatory bowel disease patients.Crohn's and colitis in children and adolescents.Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study.Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn's disease patients.A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patientsThe impact of thiopurines on surgical outcomes in inflammatory bowel disease: do they make a difference?Patterns of 6-mercaptopurine and azathioprine maintenance therapy among a cohort of commercially insured individuals diagnosed with Crohn's disease in the United States.Clinical use of probiotics in the pediatric population.Managing inflammatory bowel disease in adolescent patientsNutritional considerations in pediatric inflammatory bowel disease.Thiopurine therapy in inflammatory bowel disease.Immunomodulators for all patients with inflammatory bowel disease?Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.Optimization of conventional therapy in patients with IBD.Recent advances using immunomodulators for inflammatory bowel disease.Advances in the medical management of paediatric IBD.Crohn disease and ulcerative colitis in children: an update for 2014.Thiopurine-induced pancreatitis in inflammatory bowel diseases.Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO).Incidence of Bowel Surgery and Associated Risk Factors in Pediatric-Onset Crohn's Disease.The future developments in inflammatory bowel disease care.Time to Relapse in Children with Crohn's Disease Treated with Azathioprine and Nutritional Therapy or Corticosteroids.Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease: a national population-based study.VAlidation of an 8-item-questionnaire predictive for a positive caLprotectin tEst and Real-life implemenTation in primary care to reduce diagnostic delay in inflammatory bowel disease (ALERT): protocol for a prospective diagnostic study.Pediatric Crohn's disease activity at diagnosis, its influence on pediatrician's prescribing behavior, and clinical outcome 5 years later.Physician density and hospitalization for inflammatory bowel disease.Perceptions of medication safety among patients with inflammatory bowel disease.Risk factors for relapse and surgery rate in children with Crohn's disease.Give me prednisone and give me death.Diagnostic Considerations in Pediatric Inflammatory Bowel Disease Management.Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate.
P2860
Q26861725-2E33C3A0-F330-4DA6-B2F3-CB9F48205D36Q33595056-3EFA2D48-DE58-468A-A44C-38814867E867Q33621267-3A7BE1A3-6287-4490-B76D-01E81CCC2C8DQ33941262-E9C82F91-10CD-4ED5-8DA6-D3CFABBD052EQ33958703-BAAF2CD1-FB30-4248-AEC7-A8913F7301FDQ34235370-533748A9-9150-495A-859E-B6359AF411D0Q34367007-B431BA38-F5E7-41BA-8D4C-9BD32D52FAC0Q34610205-F8529F9D-483F-4A26-BEB3-3F9C21642DC4Q36056969-4D4B9E3E-FBA5-4291-9D49-5FCDB2337D08Q36378775-BFA3FE0C-275D-48E5-9594-3746B1344368Q36983642-AA70CBF9-AE5D-4C2E-906B-A8D49BE97226Q37146097-FD85EC08-453E-42CB-8D4B-51C5EE08B400Q37247764-4EF33EBF-9EBD-4548-ACF8-6DD1F06AF833Q37277894-CEA9B51C-33E6-41AA-9F2E-5AE2F0848541Q37378129-0BCDC1B3-68FF-41BE-903B-E7F1CB7EEC6CQ37401597-6C148B25-2C7E-4489-9A10-99BFB0259D93Q37641463-751DC5B0-A31E-418E-8769-4F3812887C52Q37763081-19EC79D2-CB78-4427-903E-9CAD4B2628D8Q37798819-4D4D4A23-8197-48E3-9FF3-FE9207741BDCQ37823320-37207EE9-8D3F-4820-B37B-62B22E1BE75AQ37936394-607FB280-8B61-4AE3-A58F-D9A5BBF75200Q37942292-4A8E281D-F03A-4003-BFCA-1C5100E88690Q38081399-6367AC31-0BD3-4917-B965-E30A23809B97Q38130044-A54B21BB-F06B-4A25-9A73-247082D8C7ACQ38231298-1E910221-9DFF-48F3-A986-109B49F3D4F2Q38286123-B5EBDFA5-F39B-4ACF-9EE1-55F284B0FAACQ38563075-F0FDE50E-3A45-47FE-9CA4-32553A746287Q38684176-3DB28B8E-2D96-4745-BD01-5AF8E82C00B5Q39276665-BF8DA7F3-FAF4-4AF3-B839-A9C97FA4BFAEQ39594232-F8206473-5260-42D6-92D0-58A65BC9FEC6Q39925453-05C6EFEE-2815-46AF-972D-E895ABEB1E52Q41485331-B560651D-8D88-472B-AE29-C9006B4CB35BQ41883343-61A15FD7-6893-4EF6-9D81-D7B326238138Q43544886-783A86BB-364E-43CB-954A-96C567D542EEQ44685457-CFB5B3B4-6A5C-4333-BEFA-1DED199E4488Q44871580-6B119CDE-2FBC-4965-A479-C7104E2D09E0Q45338340-711FCC64-74B6-4351-AF26-60CAAD1BA49EQ46189963-BE8F6079-2F9D-468B-A195-399F71AAFF03Q49348234-BE8579B8-54FD-4CDF-886C-83E5AA8E3E13Q50779337-542619BA-F3EA-41C0-85CB-8CD458FCA9C1
P2860
Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.
@en
Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.
@nl
type
label
Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.
@en
Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.
@nl
prefLabel
Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.
@en
Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.
@nl
P2093
P2860
P50
P356
P1476
Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.
@en
P2093
Adam Mezoff
Anne Griffiths
Anthony Otley
Athos Bousvaros
David Keljo
David Mack
James Markowitz
Jaya Punati
Jeffrey Hyams
P2860
P304
P356
10.1002/IBD.20412
P577
2008-07-01T00:00:00Z